Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05318443 | A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 512 | Shanghai Institute Of Biological ProductsINDUSTRY | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03607656 | The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer(CHANGE) | completed | Phase 2 / Phase 3 | 270 | Shanghai University of Traditional Chinese MedicineOTHER | 1 |
| Dec 18, 2023 |
| clinicaltrials |
| NCT01515748 | Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer(PRODIGY) | completed | Phase 3 | 530 | SanofiINDUSTRY | 1 | Dec 13, 2023 | clinicaltrials |
| NCT01864746 | A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery(PENELOPE-B) | completed | Phase 3 | 1,250 | GBG Forschungs GmbHOTHER | 11 | Dec 12, 2023 | clinicaltrials |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | completed | Phase 3 | 556 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Dec 11, 2023 | clinicaltrials |
| NCT02422615 | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-3) | completed | Phase 3 | 726 | Novartis PharmaceuticalsINDUSTRY | 30 | Nov 30, 2023 | clinicaltrials |
| NCT04239716 | Regional Anesthesia for Modified Radical Mastectomy With Axillary Lymph Node Dissection | completed | Phase 3 | 13 | Tanta UniversityOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT00606866 | MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma(MRI) | completed | Phase 3 | 57 | University of ChicagoOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03001869 | 68Ga-PSMA PET/CT in Prostate Cancer | completed | Phase 3 | 540 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT03802240 | Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure | completed | Phase 3 | 492 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT00584532 | Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.(GCP) | completed | Phase 2 / Phase 3 | 66 | University of California, DavisOTHER | 0 | Nov 24, 2023 | clinicaltrials |
| NCT01502280 | Fluorescence-guided Surgery for Low- and High-grade Gliomas(BALANCE) | completed | Phase 3 | 127 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04187352 | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 540 | CStone PharmaceuticalsINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05372016 | Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 3 | 1,200 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT02369016 | Phase III Copanlisib in Rituximab-refractory iNHL(CHRONOS-2) | completed | Phase 3 | 25 | BayerINDUSTRY | 10 | Nov 18, 2023 | clinicaltrials |
| NCT03414983 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread(CheckMate 9X8) | completed | Phase 2 / Phase 3 | 196 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 18, 2023 | clinicaltrials |
| NCT04145531 | An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) | completed | Phase 2 / Phase 3 | 229 | Jazz PharmaceuticalsINDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT02178956 | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer(BRIGHTER) | completed | Phase 3 | 714 | Sumitomo Pharma America, Inc.INDUSTRY | 22 | Nov 15, 2023 | clinicaltrials |
| NCT02753127 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer(CanStem303C) | completed | Phase 3 | 1,253 | Sumitomo Pharma America, Inc.INDUSTRY | 16 | Nov 15, 2023 | clinicaltrials |
| NCT02993731 | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma(CanStem111P) | completed | Phase 3 | 1,134 | Sumitomo Pharma America, Inc.INDUSTRY | 20 | Nov 15, 2023 | clinicaltrials |
| NCT03149003 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | completed | Phase 3 | 221 | Sumitomo Pharma America, Inc.INDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT01774721 | ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | completed | Phase 3 | 452 | PfizerINDUSTRY | 7 | Nov 14, 2023 | clinicaltrials |
| NCT00541047 | RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery | completed | Phase 3 | 4,236 | University College, LondonOTHER | 2 | Nov 13, 2023 | clinicaltrials |
| NCT05197257 | 68Ga-PSMA-11 PET in Patients With Prostate Cancer | completed | Phase 3 | 39 | University of Colorado, DenverOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT00716976 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | completed | Phase 3 | 131 | Children's Oncology GroupNETWORK | 3 | Nov 9, 2023 | clinicaltrials |
| NCT03200236 | The Lung Screening, Tobacco and Health Project | completed | Phase 3 | 1,114 | Georgetown UniversityOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT02394795 | Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC(PARADIGM) | completed | Phase 3 | 823 | TakedaINDUSTRY | 1 | Nov 1, 2023 | clinicaltrials |
| NCT04303013 | Guided Meditation During Radiotherapy. | completed | Phase 3 | 75 | Mayo ClinicOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06107790 | Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer | completed | Phase 3 | 570 | Zhejiang Hisun Pharmaceutical Co. Ltd.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer(IMpassion031) | completed | Phase 3 | 333 | Hoffmann-La RocheINDUSTRY | 13 | Oct 26, 2023 | clinicaltrials |
| NCT02617485 | MabionCD20 Compared to MabThera in Lymphoma Patients(MADILYM) | completed | Phase 3 | 143 | Mabion SAINDUSTRY | 7 | Oct 25, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | completed | Phase 3 | 746 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Oct 24, 2023 | clinicaltrials |
| NCT03434379 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma(IMbrave150) | completed | Phase 3 | 558 | Hoffmann-La RocheINDUSTRY | 17 | Oct 23, 2023 | clinicaltrials |
| NCT03262935 | SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer(TULIP) | completed | Phase 3 | 437 | Byondis B.V.INDUSTRY | 11 | Oct 19, 2023 | clinicaltrials |
| NCT02005471 | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)(MURANO) | completed | Phase 3 | 389 | Hoffmann-La RocheINDUSTRY | 20 | Oct 17, 2023 | clinicaltrials |
| NCT03040726 | Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer | completed | Phase 2 / Phase 3 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02551237 | Neoadjuvant Treatment for Advanced Rectal Carcinoma(NACRE) | completed | Phase 3 | 103 | UNICANCEROTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT02068092 | Olive Oil for High Risk Breast Cancer Prevention in Women | completed | Phase 2 / Phase 3 | 51 | The Methodist Hospital Research InstituteOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02125461 | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC) | completed | Phase 3 | 713 | AstraZenecaINDUSTRY | 26 | Oct 10, 2023 | clinicaltrials |
| NCT02987543 | Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study) | completed | Phase 3 | 387 | AstraZenecaINDUSTRY | 20 | Oct 6, 2023 | clinicaltrials |
| NCT02709512 | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(ATOMIC) | completed | Phase 2 / Phase 3 | 249 | Polaris GroupINDUSTRY | 5 | Oct 4, 2023 | clinicaltrials |
| NCT02864251 | A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy(CheckMate722) | completed | Phase 3 | 367 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 28, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03302234 | Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | completed | Phase 3 | 568 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Sep 26, 2023 | clinicaltrials |
| NCT01864850 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC(ELAN-RT) | completed | Phase 3 | 202 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT02004522 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | completed | Phase 3 | 319 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
| NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | completed | Phase 3 | 99 | SecuraBioINDUSTRY | 11 | Sep 21, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Dec 27, 2023source: clinicaltrials